drugset / Trial / NCT05391022

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

NCT05391022

Phase 1 Completed 35 enrolled Constellation Pharmaceuticals
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignancies

Timeline

Start
2021-07-20
Primary completion
2023-03-08
Completion
2024-02-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Pelabresib Small molecule